412
Participants
Start Date
April 29, 2021
Primary Completion Date
May 9, 2022
Study Completion Date
May 9, 2022
TP-03
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
TP-03 Vehicle
Vehicle of TP-03 ophthalmic solution, administered twice a day
Northern Ophthalmic Associates, Jenkintown
New River Vision Care, Oak Hill
NC Eye Associates, Apex
Vita Eye Clinic, Shelby
Pure Ophthalmic Research, Mint Hill
Pinnacle Research Institute, Fort Lauderdale
The Eye Care Institute, Louisville
Michael Washburn Center for Ophthalmic Research LLC, Indianapolis
Pankratz Eye Institute, Columbus
Complete Eye Care of Medina, Medina
Jackson Eye, S.C., Lake Villa
Ophthalmology Associates, St Louis
Tauber Eye Center, Kansas City
Kannarr Eye Care, Pittsburg
Vision Institute, Colorado Springs
Alpine Research Organization / Healthy Heart Clinics of America, Clinton
Alpine Research Organization Inc./ Country Hills Eye Center, Ogden
Global Retina Institute, Scottsdale
Shultz Chang Vision, Northridge
East Bay Eye Center, San Ramon
Periman Eye Institute, Seattle
Tarsus Pharmaceuticals, Inc.
INDUSTRY